CN115551508A - 轻度认知障碍治疗剂 - Google Patents

轻度认知障碍治疗剂 Download PDF

Info

Publication number
CN115551508A
CN115551508A CN202180034439.4A CN202180034439A CN115551508A CN 115551508 A CN115551508 A CN 115551508A CN 202180034439 A CN202180034439 A CN 202180034439A CN 115551508 A CN115551508 A CN 115551508A
Authority
CN
China
Prior art keywords
opc
cilostazol
cognitive impairment
dementia
mild cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034439.4A
Other languages
English (en)
Chinese (zh)
Inventor
川上大辅
猪原匡史
齐藤聪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shimadzu Corp
National Cerebral and Cardiovascular Center
Original Assignee
Shimadzu Corp
National Cerebral and Cardiovascular Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shimadzu Corp, National Cerebral and Cardiovascular Center filed Critical Shimadzu Corp
Publication of CN115551508A publication Critical patent/CN115551508A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202180034439.4A 2020-05-11 2021-05-06 轻度认知障碍治疗剂 Pending CN115551508A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-083163 2020-05-11
JP2020083163 2020-05-11
PCT/JP2021/017368 WO2021230131A1 (ja) 2020-05-11 2021-05-06 軽度認知障害治療剤

Publications (1)

Publication Number Publication Date
CN115551508A true CN115551508A (zh) 2022-12-30

Family

ID=78525720

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034439.4A Pending CN115551508A (zh) 2020-05-11 2021-05-06 轻度认知障碍治疗剂

Country Status (5)

Country Link
US (1) US20230270737A1 (https=)
EP (1) EP4151213A4 (https=)
JP (2) JP7587218B2 (https=)
CN (1) CN115551508A (https=)
WO (1) WO2021230131A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187075A1 (ja) * 2012-06-15 2013-12-19 公益財団法人先端医療振興財団 軽度認知障害の予防および／または治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
KR20120010800A (ko) * 2010-07-27 2012-02-06 인제대학교 산학협력단 실로스타졸 또는 이의 약리학적 허용가능한 염을 유효성분으로 함유하는 퇴행성 신경질환 치료 및 예방용 약학조성물
CN108430474A (zh) * 2015-12-25 2018-08-21 大塚制药株式会社 包含阿立哌唑和西洛他唑的药物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187075A1 (ja) * 2012-06-15 2013-12-19 公益財団法人先端医療振興財団 軽度認知障害の予防および／または治療剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAKI, TAKAKUNI ET AL.: "Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid", 《ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY》, vol. 1, no. 8, pages 519 - 533, XP055867442, DOI: 10.1002/acn3.79 *
高建，陈纭主编: "《药学（士）资格考试精讲与历年考点串讲》", 30 April 2020, 北京：中国医药科技出版社, pages: 313 *

Also Published As

Publication number Publication date
US20230270737A1 (en) 2023-08-31
WO2021230131A1 (ja) 2021-11-18
JP7587218B2 (ja) 2024-11-20
EP4151213A4 (en) 2024-05-29
EP4151213A1 (en) 2023-03-22
JP2025010627A (ja) 2025-01-22
JPWO2021230131A1 (https=) 2021-11-18

Similar Documents

Publication Publication Date Title
DIAMANT et al. The effect of montelukast (MK‐0476), a cysteinyl leukotriene receptor antagonist, on allergen‐induced airway responses and sputum cell counts in asthma
JP6037615B2 (ja) 肝性脳症を治療する方法
Storms et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged≥ 6 years
US12358870B2 (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
JP3635346B2 (ja) 中枢神経異常及びフェニルケトン尿症の診断剤及び診断方法
Morain et al. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study
Hümpel et al. The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C
González et al. Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity
CN114269722B (zh) 麦角硫因、s-甲基-麦角硫因及其用途
CN104483407B (zh) 血样中微量伊马替尼测定方法及在零期临床试验中的应用
WO2009114865A2 (en) Methods to determine susceptibility to treatment with leukotriene modifiers
EP2887066B1 (en) Composition for use in a method for measuring carbohydrate metabolism ability
Connor et al. The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori
CN115551508A (zh) 轻度认知障碍治疗剂
Oostendorp et al. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors
Johansson et al. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients
JP5213702B2 (ja) ディスペプシア診断検査薬
Medline et al. Liver granulomas and allopurinol
Leikauf et al. Sulfidopeptide leukotrienes mediate acrolein-induced bronchial hyperresponsiveness
Takagi et al. Comparative studies on interaction between theophylline and quinolones
KR20110136826A (ko) 신규의 인지기능장해 치료제
Setnikar et al. Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation
Rose et al. Non-polar urinary metabolites of chlorpromazine in male schizophrenics
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
EP3540439A1 (en) Method for assessing sugar uptake ability of liver

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20221230

RJ01 Rejection of invention patent application after publication